Desmopressin vs Lanreotide
Overview
Desmopressin and Lanreotide are both hormonal peptides, but they differ in mechanism, dosing, and regulatory status.
This page compares Desmopressin and Lanreotide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Desmopressin | Lanreotide | |
|---|---|---|
| Category | Hormonal | Hormonal |
| Regulatory status (US) | FDA approved | FDA approved |
| Typical dosage | 0.1–0.8 mg/day oral (central DI); 0.3 mcg/kg IV (hemostasis, max 20 mcg); 0.2–0.6 mg at bedtime (nocturnal enuresis); 27.7–55.3 mcg sublingual (nocturia) | 60-120 mg |
| Frequency | Once to twice daily (oral); single IV infusion or every 8–12 hours (hemostasis); once nightly (nocturia) | every 4 weeks |
| Reported benefits | central diabetes insipidus management, primary nocturnal enuresis in children, nocturia due to nocturnal polyuria, perioperative hemostasis in mild hemophilia A, hemostasis in Type I von Willebrand disease, management of polyuria following head trauma or pituitary surgery | suppression of excess growth hormone and IGF-1 in acromegaly, improved progression-free survival in GEP-NETs, reduction of carcinoid syndrome symptoms, inhibition of multiple GI and pancreatic hormones |
| Reported side effects | hyponatremia (boxed warning), headache, facial flushing, nausea, abdominal cramps, fluid retention, hypotension, reflex tachycardia, hypertension, tachyphylaxis with repeated dosing, rare anaphylaxis | diarrhea, cholelithiasis, abdominal pain, hyperglycemia, bradycardia, injection site reactions, nausea, hypertension, headache, thyroid function decreases |
Key differences
Primary use. Desmopressin is categorised under Hormonal, while Lanreotide falls under Hormonal. Because they target a similar goal, they are common alternatives to weigh against each other.
Regulatory status. Desmopressin: FDA-approved. Lanreotide: FDA-approved.
Dosing. Desmopressin is typically dosed at 0.1–0.8 mg/day oral (central DI); 0.3 mcg/kg IV (hemostasis, max 20 mcg); 0.2–0.6 mg at bedtime (nocturnal enuresis); 27.7–55.3 mcg sublingual (nocturia) (Once to twice daily (oral); single IV infusion or every 8–12 hours (hemostasis); once nightly (nocturia)). Lanreotide is typically dosed at 60-120 mg (every 4 weeks).
Can you stack them?
Some protocols combine peptides, but stacking Desmopressin and Lanreotide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Desmopressin and Lanreotide?
- Desmopressin and Lanreotide are both hormonal peptides, but they differ in mechanism, dosing, and regulatory status. Desmopressin is FDA-approved for one or more indications, whereas Lanreotide is FDA-approved for one or more indications.
- What is Desmopressin used for?
- Synthetic ADH analog (DDAVP) FDA-approved for diabetes insipidus, nocturnal enuresis, and bleeding disorders.
- What is Lanreotide used for?
- FDA-approved long-acting somatostatin analog for acromegaly, GEP-NETs, and carcinoid syndrome.
- Can you take Desmopressin and Lanreotide together?
- Some users combine peptides within a single protocol, but stacking Desmopressin and Lanreotide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Desmopressin or Lanreotide FDA-approved?
- Desmopressin is FDA-approved for one or more indications. Lanreotide is FDA-approved for one or more indications.
Read the full articles
- Desmopressin — full monograph: mechanism, research, dosing & references
- Lanreotide — full monograph: mechanism, research, dosing & references